Dermatology Times

DECEMBER 11, 2024

Discover 2024 skin cancer breakthroughs, including FDA approvals, innovative therapies, and updated clinical guidelines for melanoma and nonmelanoma care.

Innovations 69

Innovations Therapy Clinic 69

Skin Inc

DECEMBER 11, 2024

This term "collagen banking" has exploded in the past year, as a way to describe the process of amping up collagen production to ensure you have more of it later.

Collagen 59

Collagen Facials Treatments 59

Dermatology Times

DECEMBER 11, 2024

Researchers found two-thirds of patients reported no impact of psoriasis on their quality of life after 52 weeks of treatment with deucravacitinib.

Treatments 69

Treatments 69

Beauty Launchpad

DECEMBER 11, 2024

Attitudes towards charging a Green Fee are being assessed this month in a new study organized by Sustain Beauty Co.

Sustainability 52

Sustainability 52

Skin Inc

DECEMBER 11, 2024

Master Chemist Sam Dhatt On Innovative Ingredients In The Skin Care Industry, Perfecting His Formulations And Efficacy Of Products

Innovations 52

Innovations Ingredients 52

The Eco Well Podcasts

DECEMBER 11, 2024

There was a lot wrong in the recent Huberman podcast featuring Shanna Swan - the misinformation was rapid fire. This episode features Lyle Burgoon PhD in a toxicologist reacts episode to break down some of the things that came up. From phthalates = endocrine disruptors? to feminization and the threat of human extinction?? There was a lot there, but we tried our best to cover their main points.

52

52

US Dermatologt Partners

DECEMBER 11, 2024

Find expert care with a dermatologist in Sterling, CO. Specializing in acne, eczema, skin cancer, and more. Schedule your appointment today!

Dermatology 41

Dermatology Eczema 41

Dermatology Times

DECEMBER 11, 2024

2024 saw significant progress in vitiligo treatments, including novel drugs, off-label uses, and updated pediatric guidelines for better outcomes.

Treatments 41

Treatments 41

Skin Inc

DECEMBER 11, 2024

We took a peek at how spas across the country are offering self care to the clientele, and we selected these spas for their unique and effective approach to self care.

Treatments 40

Treatments 40

Spa Industry Association

DECEMBER 11, 2024

Allan experiences and shares his thoughts on OptiStrips. Silicone strips for comfortable glasses wear. Continue reading OptiStrips…adding comfort to wearing glasses at Spa Industry Association.

40

40

Dermatology Times

DECEMBER 11, 2024

The study found that those who worked with wet hands and had chapped skin had a higher severity of chronic hand eczema.

Eczema 36

Eczema 36

The Dermatology Digest

DECEMBER 11, 2024

The U.S. Food and Drug Administration (FDA) has cleared Astria Therapeutics Investigational New Drug (IND) application to study STAR-0310 in atopic dermatitis (AD). STAR-0310 is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. A Phase 1a trial of STAR-0310 in healthy subjects is expected to initiate in the first quarter of 2025, with early proof-of-concept results expected in the third quarter of 2025.

Dermatitis 36

Dermatitis Office Medical Dermatology 36

Dermatology Times

DECEMBER 11, 2024

Although further trials are needed, this multidimensional, minimally invasive approach showed positive results in 4 patients.

28

28

The Dermatology Digest

DECEMBER 11, 2024

Veradermics closed a $75 million Series B financing which will be used to fund the ongoing pivotal clinical development of VDPHL01 for the treatment of androgenetic alopecia (AGA). VDPHL01 is a non-hormonal oral therapeutic. The first patient has been dosed in the pivotal Phase 2/3 trial evaluating VDPHL01 in AGA. The trial will enroll approximately 480 patients across 44 sites in the United States.

Office 36

Office Management Innovations Clinic 36

Rosy Salon Software

DECEMBER 11, 2024

It’s been said that hairdressers are like therapists. For those of us who’ve tirelessly worked behind the chair doing hair while clients unload about their day, latest love or heartbreak, greatest achievement or recent failure, we know – to a very large degree – it’s true.

Salon 52

Salon 52

The Dermatology Digest

DECEMBER 11, 2024

AnaptysBio, Inc.is pulling the plug on ANB032, an investigational B and T lymphocyte attenuator (BTLA )agonist that did not meet the primary and secondary endpoints in an atopic dermatitis (AD) study. The drug was being studied as a monotherapy for moderate-to-severe AD in the global, 201-patient ARISE-AD trial. Despite disappointing efficacy, ANB032 was well tolerated with no safety signals observed, the Company reported.

Safety 36

Safety Dermatitis Therapy Dermatology 36